Fabhalta (Iptacopan HCl) Patent Expiration, LOE Window & CMS Spending
Fabhalta (Iptacopan HCl) by Novartis: FDA Orange Book core substance LOE 2041-05-25 (last listed 2041-07-15), 0 AB generics, $43.3M 2024 CMS Part D & Medicaid spend, and $45,205 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N218276 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-05-25 |
| Last Listed Patent or Exclusivity Date | 2041-07-15 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $43.3M |
| 2024 Medicare Part D Spend | $32.5M |
| 2024 Medicaid Spend | $10.8M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($45,205 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.